Ruxolitinib

From Anvita Health Wiki

Contents 1 Indications 2 Dosage 3 Adverse-effects 4 Mechanism-of-action 5 More General Terms 6 References

Indications

• 1st FDA-approved drug for treatment of myelofibrosis

Dosage

• oral medication taken BID

• Tabs: 5, 10, 15, 20, 25 mg

Adverse-effects

• thrombocytopenia
• anemia
• fatigue
• diarrhea
• dyspnea
• headache
• dizziness
• nausea
• confusion

Mechanism-of-action

• inhibits JAK1 & JAK2
• reduces myelofibrosis-related symptoms, including splenomegaly, abdominal pain, night sweats, bone or muscle pain, itching

More General Terms

• antineoplastic agent (chemotherapeutic agent)
• enzyme inhibitor

References

1. Chestecka Z Medscape Oncology, 11/16/2011 FDA Approves Ruxolitinib, First Drug Ever for Myelofibrosis [1]

ruxolitinib